2023
164-LB: Durable Improvement in HbA1c in Youth-Onset T2D—A Post Hoc Analysis of the DINAMO Trial of Empagliflozin and Linagliptin vs. Placebo
LAFFEL L, DANNE T, TAMBORLANE W, KLINGENSMITH G, NEUBACHER D, TARTAKOVSKY I, MARQUARD J, ZEITLER P, WILLI S. 164-LB: Durable Improvement in HbA1c in Youth-Onset T2D—A Post Hoc Analysis of the DINAMO Trial of Empagliflozin and Linagliptin vs. Placebo. Diabetes 2023, 72 DOI: 10.2337/db23-164-lb.Peer-Reviewed Original ResearchHbA1c <Increasing prevalence of childhood overweightGlycemic controlPrevalence of childhood overweightSafety of empagliflozinLinagliptin 5 mgClinically meaningful responseYouth-onset T2DOnset of complicationsBeta-cell functionPost hoc analysisEmpagliflozin groupClinical courseFPG levelsChildhood overweightSGLT2 inhibitorsEmpagliflozinYouth-onsetPlaceboHbA1c changeMeaningful responseHbA1cHigher HbA1cHoc analysisIncreased prevalence
2019
Biologic and social factors predict incident kidney disease in type 1 diabetes: Results from the T1D exchange clinic network
McGill JB, Wu M, Pop-Busui R, Mizokami-Stout K, Tamborlane WV, Aleppo G, Gubitosi-Klug RA, Haller MJ, Willi SM, Foster NC, Zimmerman C, Libman I, Polsky S, Rickels MR. Biologic and social factors predict incident kidney disease in type 1 diabetes: Results from the T1D exchange clinic network. Journal Of Diabetes And Its Complications 2019, 33: 107400. PMID: 31279735, DOI: 10.1016/j.jdiacomp.2019.06.005.Peer-Reviewed Original ResearchConceptsAdverse kidney outcomesDiabetic kidney diseaseKidney outcomesType 1 diabetesKidney diseaseRisk factorsRisk of DKDDevelopment of DKDT1D Exchange Clinic NetworkAlbumin/creatinine ratioIncident kidney diseaseBlood pressure controlModifiable risk factorsT1D Exchange RegistryUrine albumin measurementsLow education levelModern clinical practiceEGFR declineIncident albuminuriaT1D durationBaseline characteristicsSerum creatinineCreatinine ratioMajor complicationsHigher HbA1c
2018
Adolescent type 2 diabetes: Comparing the Pediatric Diabetes Consortium and Germany/Austria/Luxemburg Pediatric Diabetes Prospective registries
Klingensmith GJ, Lanzinger S, Tamborlane WV, Hofer SE, Cheng P, de Beaufort C, Gal RL, Reinehr T, Kollman C, Holl RW. Adolescent type 2 diabetes: Comparing the Pediatric Diabetes Consortium and Germany/Austria/Luxemburg Pediatric Diabetes Prospective registries. Pediatric Diabetes 2018, 19: 1156-1163. PMID: 29923263, DOI: 10.1111/pedi.12712.Peer-Reviewed Original ResearchConceptsDiabetes durationClinical characteristicsBody mass index SDSAdolescent type 2Onset of T2DPediatric Diabetes ConsortiumShorter diabetes durationMost recent visitType 2 diabetesYears of ageProspective registryTreatment of youthAdverse eventsDiabetes complicationsHigher HbA1cOffice visitsHigher hemoglobinUnited States databaseVs 3.2Diabetes testingType 2RegistryLaboratory dataTreatment differencesFurther studies
2013
Severe hypoglycemia and diabetic ketoacidosis among youth with type 1 diabetes in the T1D Exchange clinic registry
Cengiz E, Xing D, Wong JC, Wolfsdorf JI, Haymond MW, Rewers A, Shanmugham S, Tamborlane WV, Willi SM, Seiple DL, Miller KM, DuBose SN, Beck RW, Network F. Severe hypoglycemia and diabetic ketoacidosis among youth with type 1 diabetes in the T1D Exchange clinic registry. Pediatric Diabetes 2013, 14: 447-454. PMID: 23469984, PMCID: PMC4100244, DOI: 10.1111/pedi.12030.Peer-Reviewed Original ResearchConceptsType 1 diabetesT1D Exchange Clinic RegistryDiabetic ketoacidosisSevere hypoglycemiaClinic registryFrequency of SHOccurrence of SHRisk of DKASerious acute complicationsPoor glycemic controlHigh-risk groupAssociation of baselineNew treatment paradigmSeparate logistic regression modelsNon-white raceLower household incomeLogistic regression modelsYoung adult cohortDKA frequencyAcute complicationsClinical factorsGlycemic controlHigher HbA1cT1D ExchangeTreatment paradigm